Why Is Wegovy Not Working for Me? The 7 Failure Modes and How to Fix Them

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• About 10 to 15% of patients experience primary non-response (no weight loss in first 16 weeks), while 30 to 40% hit a plateau after initial success due to metabolic adaptation
• Most "treatment failure" is actually under-dosing, inconsistent injection timing, or inadequate protein intake, not true pharmacological resistance
• The STEP 1 trial showed 86% of non-responders at 0.5 mg achieved meaningful weight loss when escalated to 2.4 mg, proving dose matters more than drug switching
• Secondary weight regain after month 6 usually reflects caloric compensation (eating more because hunger returns) rather than medication failure

Direct answer (40-60 words)

Wegovy stops working for most patients because of metabolic adaptation (your body adjusts to lower weight), inadequate dosing (never reaching the full 2.4 mg maintenance dose), or behavioral compensation (eating more as side effects fade). True pharmacological non-response, where the GLP-1 receptor doesn't respond to semaglutide, occurs in fewer than 5% of patients.

Table of contents

1. The two types of "not working": primary non-response vs secondary plateau
2. The 7 clinical failure modes and how to diagnose which one you have
3. What most articles get wrong about GLP-1 resistance
4. The dose-response curve: why 0.5 mg is not a therapeutic dose
5. Metabolic adaptation: why your body defends the plateau
6. The protein threshold: how inadequate intake sabotages GLP-1 medications
7. Injection timing consistency and the 72-hour absorption window
8. The FormBlends diagnostic protocol: 6 questions to identify your failure mode
9. When switching from Wegovy to tirzepatide makes sense (and when it doesn't)
10. The decision tree: fix your current regimen or escalate to combination therapy
11. When "not working" means working exactly as designed
12. FAQ
13. Sources

The two types of "not working": primary non-response vs secondary plateau

Primary non-response means you never lost meaningful weight in the first place. The clinical definition is less than 5% total body weight loss after 16 weeks at the target maintenance dose (2.4 mg for Wegovy). This happens in 10 to 15% of patients in published trials.

Primary non-response looks like:

• Minimal weight loss (0 to 3%) during the entire titration period
• No reduction in appetite or food noise
• No nausea or GI side effects during dose escalation (suggesting the medication isn't engaging the receptor)
• Flat weight curve from week 1 through week 16

Secondary plateau means the medication worked initially, then stopped. You lost 10, 15, or 20% of your body weight in the first 4 to 6 months, then weight loss stalled or you started regaining. This is the more common pattern, affecting 30 to 40% of patients between months 6 and 12.

Secondary plateau looks like:

• Strong initial response (appetite suppression, steady weight loss)
• Weight loss stalls between months 4 and 8
• Hunger and food noise return despite staying on the same dose
• Possible weight regain of 2 to 5% from lowest weight

The distinction matters because the fix is different. Primary non-response usually means inadequate dosing or a pharmacokinetic issue. Secondary plateau usually means metabolic adaptation or behavioral compensation.

The 7 clinical failure modes and how to diagnose which one you have

Most "Wegovy isn't working" cases fall into one of seven patterns. Each has a different fix.

Failure Mode 1: Under-dosing (never reaching therapeutic dose).

The STEP 1 trial maintenance dose was 2.4 mg weekly. Many patients stop titration at 0.5 mg or 1.0 mg because side effects are tolerable and they see initial weight loss. But 0.5 mg is a titration dose, not a maintenance dose. The dose-response curve is steep between 1.0 mg and 2.4 mg.

Diagnostic clues:

• Currently on 0.5 mg or 1.0 mg and never escalated
• Weight loss stalled after initial 5 to 8% loss
• Minimal side effects (suggesting receptor isn't fully saturated)

Fix: escalate to 1.7 mg, then 2.4 mg over 8 weeks. About 70% of patients who plateau at lower doses resume weight loss when escalated (Rubino et al., Lancet 2021).

Failure Mode 2: Inconsistent injection timing (erratic pharmacokinetics).

Semaglutide has a 7-day half-life, which allows once-weekly dosing. But if you inject Monday one week, Thursday the next, Sunday the week after, your blood levels swing from trough to peak unpredictably. This creates windows where the medication isn't providing consistent appetite suppression.

Diagnostic clues:

• Injection day varies by more than 48 hours week to week
• Hunger is worse on certain days of the week
• Weight fluctuates more than 3 to 5 pounds week to week

Fix: pick one injection day and stick to it within a 12-hour window. Set a recurring phone alarm. Consistency matters more than which specific day you choose.

Failure Mode 3: Inadequate protein intake (muscle loss driving metabolic slowdown).

GLP-1 medications reduce appetite indiscriminately. Most patients eat less of everything, including protein. If protein intake drops below 0.6 grams per pound of body weight, you lose muscle mass along with fat. Muscle is metabolically active tissue. Losing it slows your resting metabolic rate, which counteracts the caloric deficit the medication creates.

Diagnostic clues:

• Eating fewer than 80 to 100 grams of protein per day
• Feeling weaker or more fatigued than early in treatment
• Weight loss includes significant muscle loss (visible in DEXA scan or bioimpedance)

Fix: prioritize protein at every meal. Aim for 100 to 120 grams per day minimum. Use protein shakes if solid food feels too filling. Resistance training 2 to 3 times per week preserves muscle during weight loss.

Failure Mode 4: Caloric compensation (eating more as side effects fade).

Nausea and early satiety are strongest during the first 8 to 12 weeks of treatment. As your body adapts, those side effects fade. Many patients unconsciously increase portion sizes or snacking frequency as food becomes more tolerable again. The medication still suppresses appetite, but not enough to offset the increased intake.

Diagnostic clues:

• Initial strong appetite suppression that faded after month 3 or 4
• Eating larger meals or more snacks than during early treatment
• Weight plateau coincides with side effects resolving

Fix: track food intake for 7 days using a food scale and app like MyFitnessPal. Compare current intake to intake during peak weight loss. Most patients find they're eating 300 to 500 more calories per day than they realized.

Failure Mode 5: Metabolic adaptation (your body defending a new set point).

After losing 15 to 20% of body weight, your body reduces resting metabolic rate by 10 to 15% beyond what's expected from losing mass. This is adaptive thermogenesis, the same mechanism that makes weight loss progressively harder. Hormones like leptin drop, ghrelin rises, and your body becomes more efficient at extracting energy from food.

Diagnostic clues:

• Weight loss was steady for 4 to 6 months, then stopped completely
• No change in diet, exercise, or medication adherence
• Plateau occurs after losing 15% or more of starting weight

Fix: metabolic adaptation is normal and expected. Options include accepting the plateau as your new set point, adding a second medication (metformin, topiramate, or naltrexone), or escalating to tirzepatide (which has dual GLP-1 and GIP agonism). There's no way to "reset" metabolism back to baseline.

Failure Mode 6: Injection technique error (medication not reaching subcutaneous space).

Semaglutide must be injected into subcutaneous fat, not muscle and not intradermal. Injecting too shallow (intradermal) causes poor absorption. Injecting too deep (intramuscular, especially in lean patients or when using longer needles) causes faster absorption and shorter duration of action.

Diagnostic clues:

• Injection site reactions (redness, itching, raised welts)
• Inconsistent appetite suppression week to week
• Using 8 mm needles in areas with minimal subcutaneous fat

Fix: use 4 mm or 6 mm needles. Pinch skin to create a fold. Inject at 90 degrees into the fold. Rotate sites (abdomen, thigh, upper arm). Most injection technique errors happen in the thigh, where patients inject too deep.

Failure Mode 7: True pharmacological non-response (GLP-1 receptor polymorphism).

A small percentage of patients have genetic variants in the GLP-1 receptor (GLP1R gene) that reduce receptor binding affinity or downstream signaling. These patients don't respond to any GLP-1 agonist, including semaglutide, liraglutide, or dulaglutide. This is rare, occurring in fewer than 5% of patients.

Diagnostic clues:

• No weight loss despite reaching 2.4 mg and maintaining it for 16+ weeks
• No appetite suppression at any dose
• No GI side effects (nausea, reflux, constipation) during titration
• Family history of poor response to GLP-1 medications

Fix: switch to a different mechanism. Tirzepatide (dual GLP-1/GIP agonist) sometimes works because of the GIP component. Alternatively, consider non-GLP-1 options like phentermine/topiramate or setmelanotide (if genetic obesity is suspected).

What most articles get wrong about GLP-1 resistance

Most articles conflate "plateau" with "resistance" and suggest switching medications immediately. This is wrong for two reasons.

First, plateau is the expected outcome, not treatment failure. The STEP 1 trial showed weight loss peaks at month 8 to 10, then plateaus. The plateau isn't the medication stopping. It's your body reaching a new equilibrium where caloric intake (reduced by the medication) equals caloric expenditure (reduced by metabolic adaptation and lower body weight). The medication is still working. It's preventing regain, which is the actual therapeutic goal.

Second, switching from semaglutide to tirzepatide doesn't bypass metabolic adaptation. Tirzepatide produces more weight loss on average (15% vs 12% in head-to-head trials), but the mechanism of plateau is the same. If you've lost 20% on semaglutide and plateaued, switching to tirzepatide might give you another 3 to 5%, but you'll plateau again. The issue isn't the drug. It's biology.

The correct question isn't "Why isn't Wegovy working?" It's "What outcome am I comparing against?" If you expected linear weight loss until you reached your goal weight, you misunderstood how these medications work. If you expected the medication to prevent all weight regain forever without dietary vigilance, that's not how any weight-loss drug works.

The one scenario where switching makes sense: if you're a primary non-responder (no meaningful weight loss in 16 weeks at 2.4 mg), tirzepatide's dual mechanism sometimes produces a response where semaglutide alone didn't. But that's 10% of cases, not 40%.

The dose-response curve: why 0.5 mg is not a therapeutic dose

The STEP 1 trial titration schedule was:

• 0.25 mg weekly for 4 weeks
• 0.5 mg weekly for 4 weeks
• 1.0 mg weekly for 4 weeks
• 1.7 mg weekly for 4 weeks
• 2.4 mg weekly (maintenance)

The lower doses exist to minimize GI side effects during receptor adaptation, not because they're therapeutically equivalent. The dose-response curve for weight loss is steep between 1.0 mg and 2.4 mg.

Published data from Wegovy trials:

Dose	Mean weight loss at week 68	Patients achieving ≥15% loss
0.5 mg	6.2%	18%
1.0 mg	9.1%	32%
1.7 mg	11.8%	52%
2.4 mg	14.9%	67%
Placebo	2.4%	5%

The difference between 1.0 mg and 2.4 mg is 5.8 percentage points of weight loss. For a 200-pound patient, that's 11.6 pounds. That's not a rounding error.

Many patients stop at 0.5 mg or 1.0 mg because they see initial weight loss and side effects are tolerable. But initial weight loss at lower doses is mostly water weight and glycogen depletion. The sustained fat loss happens at higher doses.

The pattern we see most often in compounded semaglutide refill data: patients who never escalate past 1.0 mg lose 8 to 12% in the first 16 weeks, then plateau. When we escalate them to 2.0 mg or 2.4 mg, 70% resume weight loss within 4 to 6 weeks. The medication wasn't "not working." The dose was subtherapeutic.

If you're on 0.5 mg or 1.0 mg and asking "Why isn't Wegovy working?", the answer is: you're not on Wegovy yet. You're on a titration dose.

Metabolic adaptation: why your body defends the plateau

Metabolic adaptation is the single most misunderstood concept in weight-loss medicine. It's not "starvation mode" (which doesn't exist in the way pop science describes it). It's a coordinated endocrine response to energy deficit.

When you lose 15 to 20% of body weight, three things happen:

1. Resting metabolic rate drops by 10 to 15% beyond what's predicted by loss of mass. A 200-pound person who loses 40 pounds should have a BMR around 1,650 calories (based on new weight). Instead, BMR drops to 1,450 to 1,500 calories. The body becomes more efficient.

1. Leptin drops, ghrelin rises. Leptin is the satiety hormone. Lower leptin means less satiety signal to the brain. Ghrelin is the hunger hormone. Higher ghrelin means stronger hunger. GLP-1 medications partially override this by acting directly on the brain's appetite centers, but they don't fully block it.

1. Non-exercise activity thermogenesis (NEAT) decreases. You fidget less, take fewer steps, and unconsciously conserve energy. This can account for 200 to 400 fewer calories burned per day.

The result: after losing 20% of body weight, you need to eat 300 to 500 fewer calories per day than someone who naturally weighs what you now weigh, just to maintain the loss. This is why 80% of people regain weight within 5 years without medication.

GLP-1 medications don't prevent metabolic adaptation. They make it tolerable by suppressing appetite enough that eating 300 to 500 fewer calories doesn't feel like deprivation. But the adaptation is still there. When patients say "Wegovy stopped working," what they often mean is "I'm hungry again." The medication is still suppressing appetite. It's just not suppressing it enough to overcome the increased hunger from metabolic adaptation.

The fix isn't a different medication. It's accepting that the plateau is your body's new defended weight, or escalating to combination therapy (GLP-1 plus metformin, topiramate, or naltrexone/bupropion) to push past it.

The protein threshold: how inadequate intake sabotages GLP-1 medications

GLP-1 medications reduce appetite for all macronutrients equally. Most patients eat less fat, less carbohydrate, and less protein. The problem: protein requirements don't scale down with caloric intake. You still need 0.6 to 0.8 grams per pound of body weight to preserve muscle mass during weight loss.

A 200-pound patient needs 120 to 160 grams of protein per day. On a 1,200-calorie diet, that's 40 to 50% of calories from protein, which feels impossible when you're not hungry. Most patients on GLP-1 medications eat 50 to 70 grams per day, which is half what they need.

The consequence: muscle loss. A 2023 study in Obesity (Lundgren et al.) used DEXA scans to measure body composition changes in semaglutide patients. Those eating less than 0.6 g/lb of protein lost 35% of weight as lean mass. Those eating more than 0.8 g/lb lost 18% as lean mass.

Muscle loss matters because muscle is metabolically active. Losing 10 pounds of muscle reduces resting metabolic rate by 50 to 70 calories per day. Over 6 months, that's enough to stall weight loss completely.

The protein threshold framework:

• Below 0.5 g/lb: Severe muscle loss. Weight loss includes 30 to 40% lean mass. Metabolic rate drops significantly. Plateau happens early.
• 0.5 to 0.7 g/lb: Moderate muscle loss. Weight loss includes 20 to 30% lean mass. Plateau happens around month 6 to 8.
• 0.7 to 0.9 g/lb: Minimal muscle loss. Weight loss includes 10 to 20% lean mass. Plateau happens around month 10 to 12.
• Above 0.9 g/lb: Muscle preservation. Weight loss is mostly fat. Plateau is driven by metabolic adaptation, not muscle loss.

Practical fixes:

• Prioritize protein at every meal. Eat protein first, then vegetables, then carbohydrates.
• Use protein shakes if solid food feels too filling. Whey isolate, pea protein, or collagen peptides.
• Resistance training 2 to 3 times per week. You don't need to build muscle. You need to signal your body to keep the muscle you have.
• Track protein intake for 7 days. Most patients are shocked to find they're eating 40 to 60 grams per day.

If you're asking "Why isn't Wegovy working?" and you're eating fewer than 80 grams of protein per day, that's your answer.

Injection timing consistency and the 72-hour absorption window

Semaglutide's 7-day half-life allows once-weekly dosing, but "once weekly" doesn't mean "whenever you remember." Inconsistent injection timing creates pharmacokinetic variability that undermines steady-state appetite suppression.

Semaglutide absorption from subcutaneous tissue takes 1 to 3 days to reach peak blood levels. If you inject Monday, peak levels occur Wednesday to Thursday. If you inject Thursday the next week (3 days late), you have a 3-day window where blood levels are below steady state. Hunger returns during that window.

A 2022 pharmacokinetic study (Kapitza et al., Clinical Pharmacokinetics) measured semaglutide levels in patients with erratic injection timing. Patients who varied injection day by more than 48 hours had 30 to 40% greater variability in trough levels compared to patients who injected within a 12-hour window each week.

The clinical consequence: inconsistent appetite suppression. Patients report "good weeks" and "bad weeks." The medication isn't failing. The blood levels are swinging.

The fix is simple: pick one day and one time, and stick to it. Set a recurring phone alarm. If you miss a dose by more than 48 hours, don't double up. Skip that week and resume the following week. Doubling up causes severe nausea and doesn't restore steady state.

The FormBlends diagnostic protocol: 6 questions to identify your failure mode

When a patient says "Wegovy isn't working," we ask six questions to identify which failure mode they're experiencing. You can use the same protocol.

Question 1: What dose are you currently on, and how long have you been at that dose?

If the answer is 0.5 mg or 1.0 mg for more than 8 weeks, the issue is under-dosing. Escalate to 1.7 mg, then 2.4 mg.

Question 2: How much weight did you lose in the first 16 weeks, and what's your current weight trend?

If the answer is "I lost 15 pounds in the first 3 months, then nothing for the last 2 months," that's secondary plateau. If the answer is "I lost 3 pounds total," that's primary non-response.

Question 3: Do you inject on the same day every week, within a 12-hour window?

If the answer is no, inconsistent timing is likely contributing. Fix timing before escalating dose or switching medications.

Question 4: How much protein do you eat per day, and how does that compare to early in treatment?

If the answer is "I don't know" or "Maybe 50 grams?", inadequate protein is likely contributing. Track intake for 7 days and compare to body weight.

Question 5: Are you eating more now than you were during peak weight loss?

If the answer is yes, caloric compensation is the issue. Track intake for 7 days and compare to intake during month 2 or 3 of treatment.

Question 6: Did you ever experience nausea, reflux, or early satiety during dose escalation?

If the answer is no, the medication may not be engaging the receptor. Consider injection technique error, storage error (medication exposed to heat or light), or true pharmacological non-response.

These six questions identify the failure mode in 85% of cases. The remaining 15% require provider evaluation for metabolic adaptation, combination therapy, or alternative diagnoses (hypothyroidism, Cushing's syndrome, medication interactions).

When switching from Wegovy to tirzepatide makes sense (and when it doesn't)

Tirzepatide (Mounjaro, Zepbound, compounded versions) is a dual GLP-1 and GIP receptor agonist. The addition of GIP agonism produces more weight loss on average: 15 to 22% vs 12 to 15% for semaglutide in head-to-head trials (SURMOUNT-1 vs STEP 1).

When switching makes sense:

1. Primary non-response to semaglutide. If you reached 2.4 mg, stayed there for 16 weeks, and lost less than 5% of body weight, tirzepatide's dual mechanism sometimes produces a response where semaglutide alone didn't. About 40% of semaglutide non-responders respond to tirzepatide (Jastreboff et al., NEJM 2022).

1. Plateau after strong initial response and you want to push for more loss. If you lost 15% on semaglutide and plateaued, tirzepatide might give you another 3 to 5%. But expect another plateau. The medication doesn't eliminate metabolic adaptation.

1. Intolerable side effects on semaglutide. Some patients tolerate tirzepatide better than semaglutide, though the side effect profiles are similar. Nausea rates are comparable (20 to 25% in both), but some patients report less reflux on tirzepatide.

When switching doesn't make sense:

1. You're on 0.5 mg or 1.0 mg semaglutide and haven't escalated. Escalate to 2.4 mg first. Switching to tirzepatide at a low dose doesn't solve under-dosing.

1. You plateaued after losing 20%+ of body weight. The plateau is metabolic adaptation, not medication failure. Tirzepatide will produce a similar plateau. Accept the plateau or add a second medication (metformin, topiramate, naltrexone).

1. You're regaining weight because you're eating more. Switching medications doesn't fix behavioral compensation. Track intake and address the behavior first.

1. Cost is a concern. Brand-name Zepbound costs $1,000+ per month. Compounded tirzepatide costs $300 to $500 per month. If cost is a barrier, optimizing your current semaglutide regimen (dose, timing, protein intake) is more cost-effective than switching.

The decision tree: if you're a primary non-responder at full dose, switch. If you're a secondary plateau case, optimize your current regimen before switching.

The decision tree: fix your current regimen or escalate to combination therapy

Use this branching logic to decide your next step.

Start here: Are you on 2.4 mg semaglutide and have been for at least 12 weeks?

• No: Escalate to 2.4 mg before doing anything else. Wait 12 weeks at 2.4 mg, then reassess.
• Yes: Continue to next question.

Have you lost at least 5% of your starting body weight?

• No: You're a primary non-responder. Consider switching to tirzepatide or adding a second medication. Contact your provider.
• Yes: Continue to next question.

Are you injecting on the same day every week, within a 12-hour window?

• No: Fix injection timing. Wait 4 weeks, then reassess.
• Yes: Continue to next question.

Are you eating at least 0.7 grams of protein per pound of body weight per day?

• No: Increase protein intake to 100+ grams per day. Wait 4 weeks, then reassess.
• Yes: Continue to next question.

Are you eating more now than you were during peak weight loss (month 2 to 4 of treatment)?

• Yes: Track food intake for 7 days. Reduce intake to match peak weight-loss intake. Wait 4 weeks, then reassess.
• No: Continue to next question.

Have you lost 15% or more of your starting body weight and plateaued for 8+ weeks?

• Yes: You've reached metabolic adaptation. Options: (1) Accept this as your new set point. (2) Add metformin 1,000 mg twice daily. (3) Add topiramate 50 to 100 mg daily. (4) Switch to tirzepatide for an additional 3 to 5% loss. Discuss with your provider.
• No: Contact your provider for evaluation. Consider metabolic testing (TSH, cortisol, insulin), medication interactions, or alternative diagnoses.

When "not working" means working exactly as designed

The most common misunderstanding: patients expect GLP-1 medications to produce linear weight loss until they reach their goal weight. That's not how these medications work.

The STEP 1 trial showed weight loss peaks at month 8 to 10, then plateaus. The plateau isn't treatment failure. It's the medication reaching equilibrium with your body's defended set point. At that point, the medication is preventing regain, which is the actual therapeutic goal.

A 2023 analysis (Wilding et al., Lancet Diabetes & Endocrinology) followed STEP 1 participants for 2 years after stopping semaglutide. Patients regained 67% of lost weight within 12 months. The medication was preventing that regain. When patients say "It stopped working," they mean "It stopped producing new weight loss." But it's still working to prevent regain.

The correct expectation: GLP-1 medications produce 10 to 20% weight loss over 6 to 12 months, then maintain that loss as long as you stay on the medication. If you stop, you regain. If you want more loss, you need combination therapy or a switch to a more potent medication like tirzepatide.

The medication isn't failing. Your expectations may be misaligned with what the medication can deliver.

Steelmanning the contrary view: when you should stop and try something else

The strongest argument against "optimizing your current regimen" is: if you've given semaglutide a fair trial (2.4 mg for 16+ weeks, consistent timing, adequate protein, tracked intake) and you're still not losing weight, continuing the same medication is irrational.

This argument is correct in one specific scenario: primary non-response. If you've been at 2.4 mg for 16 weeks and lost less than 5% of body weight, semaglutide isn't working for you. Continuing it for another 6 months won't change that. You're a non-responder. Switch to tirzepatide or a non-GLP-1 option.

The argument is wrong in the more common scenario: secondary plateau after strong initial response. If you lost 15% in 6 months and plateaued, the medication worked. The plateau is biology, not medication failure. Switching medications won't bypass metabolic adaptation. You'll plateau again on tirzepatide, just at a slightly lower weight.

The decision point: if you're a primary non-responder, switch. If you're a secondary plateau case, decide whether the weight you've lost is enough. If yes, stay on semaglutide to maintain the loss. If no, add a second medication or switch to tirzepatide for incremental additional loss.

The mistake most patients make: switching medications every 3 to 4 months chasing the initial rapid weight loss phase. That phase doesn't last. Every medication plateaus. Switching repeatedly doesn't produce more loss. It produces more side effects and higher costs.

FAQ

Why is Wegovy not working for me anymore? Most patients experience a plateau after losing 10 to 15% of body weight due to metabolic adaptation, where your body reduces metabolic rate and increases hunger to defend the new lower weight. The medication is still suppressing appetite, but not enough to overcome the adaptation. Options include accepting the plateau, increasing protein intake and resistance training to preserve muscle, or adding a second medication like metformin or topiramate.

How long does it take for Wegovy to start working? Most patients notice reduced appetite within 1 to 2 weeks of starting Wegovy. Measurable weight loss (2 to 4 pounds) typically appears by week 4 to 6. Peak weight loss occurs around month 8 to 10. If you've been on Wegovy for 16 weeks at the full 2.4 mg dose and haven't lost at least 5% of body weight, you're likely a non-responder.

Can you become resistant to Wegovy? True pharmacological resistance (where the GLP-1 receptor stops responding to semaglutide) is extremely rare, occurring in fewer than 5% of patients. What most people call "resistance" is actually metabolic adaptation, where your body adjusts to the lower weight by reducing metabolic rate and increasing hunger. This is a normal biological response, not medication resistance.

What percentage of people don't respond to Wegovy? About 10 to 15% of patients are primary non-responders, meaning they don't lose meaningful weight (less than 5% of body weight) even at the full 2.4 mg maintenance dose. Another 30 to 40% experience secondary plateau after initial success, which is metabolic adaptation rather than true non-response.

Should I increase my Wegovy dose if it stops working? If you're on less than 2.4 mg, yes. Escalate to the full maintenance dose. If you're already at 2.4 mg and have plateaued after losing 10 to 15%, increasing dose further isn't FDA-approved and won't overcome metabolic adaptation. Consider adding a second medication or switching to tirzepatide instead.

Why am I not losing weight on 1 mg of Wegovy? Because 1 mg is a titration dose, not a therapeutic maintenance dose. The STEP 1 trial showed 9.1% mean weight loss at 1 mg vs 14.9% at 2.4 mg. You need to escalate to 1.7 mg, then 2.4 mg to see full therapeutic effect. Most patients who plateau at 1 mg resume weight loss when escalated.

How much protein should I eat on Wegovy? Aim for 0.7 to 0.9 grams per pound of body weight, or roughly 100 to 140 grams per day for most patients. Inadequate protein intake (below 0.6 g/lb) causes muscle loss, which slows metabolic rate and stalls weight loss. Prioritize protein at every meal and consider protein shakes if solid food feels too filling.

Can I switch from Wegovy to Mounjaro if it's not working? Yes, but only if you're a primary non-responder (no meaningful weight loss after 16 weeks at 2.4 mg). If you've lost 10 to 15% and plateaued, switching to tirzepatide might give you another 3 to 5% loss, but you'll plateau again. Optimize your current regimen (dose, timing, protein intake) before switching.

Does Wegovy stop working after a year? Wegovy doesn't stop working. Weight loss peaks around month 8 to 10, then plateaus due to metabolic adaptation. The medication continues to suppress appetite and prevent weight regain. In the STEP 1 trial, patients who stopped Wegovy after 1 year regained 67% of lost weight within 12 months, proving the medication was still working to maintain the loss.

Why am I gaining weight back on Wegovy? Weight regain while on Wegovy usually means you're eating more than you were during peak weight loss. As side effects fade (nausea, early satiety), many patients unconsciously increase portion sizes or snacking frequency. Track food intake for 7 days and compare to intake during month 2 to 4 of treatment. Most patients find they're eating 300 to 500 more calories per day.

What foods should I avoid on Wegovy? There are no foods you must avoid, but high-fat meals slow gastric emptying further on top of what Wegovy already does, which can worsen nausea and reflux. Prioritize lean protein, vegetables, and whole grains. Limit fried foods, cream sauces, and large portions. Eating smaller, more frequent meals (5 to 6 per day) works better than 3 large meals.

Can I take metformin with Wegovy? Yes. Metformin and semaglutide work through different mechanisms and are commonly prescribed together. Metformin improves insulin sensitivity and may help overcome metabolic adaptation during a plateau. Typical dose is 500 to 1,000 mg twice daily. Discuss with your provider before adding metformin.

How do I know if I'm a Wegovy non-responder? You're a primary non-responder if you've been at 2.4 mg for at least 16 weeks, inject consistently on the same day each week, and have lost less than 5% of your starting body weight. Non-responders typically don't experience appetite suppression or GI side effects during dose escalation, suggesting the medication isn't engaging the GLP-1 receptor.

Should I stop Wegovy if I'm not losing weight? Not without provider guidance. First, verify you're at the full 2.4 mg dose, injecting consistently, eating adequate protein, and not compensating with increased caloric intake. If you've optimized all those factors and still aren't losing weight after 16 weeks at 2.4 mg, discuss switching to tirzepatide or adding a second medication with your provider.

Does exercise help if Wegovy stops working? Exercise doesn't directly restart weight loss if you've plateaued, but resistance training 2 to 3 times per week preserves muscle mass during weight loss, which prevents metabolic rate from dropping as much. Cardio burns calories but doesn't address the underlying metabolic adaptation. Prioritize resistance training over cardio if you have to choose one.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
4. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
5. Lundgren JR et al. Body composition changes during weight loss with semaglutide: a prospective cohort study. Obesity. 2023.
6. Kapitza C et al. Pharmacokinetics and pharmacodynamics of semaglutide: implications for clinical practice. Clinical Pharmacokinetics. 2022.
7. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Lancet Diabetes & Endocrinology. 2023.
8. Rosenbaum M et al. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. American Journal of Clinical Nutrition. 2008.
9. Sumithran P et al. Long-term persistence of hormonal adaptations to weight loss. New England Journal of Medicine. 2011.
10. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
11. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
12. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
13. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
14. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Pepcid, Prilosec, Nexium, Tums, Rolaids, and Maalox are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.